Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
27,748,559
-
Total 13F shares
-
27,200,695
-
Share change
-
+13,577,455
-
Total reported value
-
$921,288,979
-
Put/Call ratio
-
1.3%
-
Price per share
-
$33.87
-
Number of holders
-
99
-
Value change
-
+$461,871,577
-
Number of buys
-
82
-
Number of sells
-
15
Institutional Holders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) as of Q4 2025
As of 31 Dec 2025,
RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) was held by
99 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,200,695 shares.
The largest 10 holders included
TCG Crossover Management, LLC, FCPM III SERVICES B.V., ORBIMED ADVISORS LLC, RTW INVESTMENTS, LP, Foresite Capital Management VI LLC, Siren, L.L.C., VANGUARD GROUP INC, Frazier Life Sciences Management, L.P., BRAIDWELL LP, and Redmile Group, LLC.
This page lists
99
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.